Orally disintegrating tablets (ODTs), which disintegrate rapidly (<1 min) in the mouth and do not require water for administration, have become a very popular dosage form. The study aims to develop a simple and inexpensive method of manufacturing ODTs of a sparingly water-soluble drug, Dextromethorphan hydrobromide. Two factors, three levels (32) full factorial design was used to optimize the diluent, microcrystalline cellulose (X1) and superdisintegrant, croscarmellose sodium (X2) concentrations. Disintegration time, hardness and T50 values for all the formulations varied from 12.5 to 152.6 s, 3.58 to 4.92 kp and 0.8 to 2.8 min, respectively. The results indicated that the selected variables have a strong influence on disintegration time, hardness and T50 of the ODTs. The manufactured ODTs formula composed of 30% microcrystalline cellulose in combination with 3% croscarmellose sodium was chosen as optimized formula, as it showed the lowest disintegration time (12.5 ± 1.22 s), low T50 (0.8 min.) and hard tablets (4.92 ± 0.28 kp) amongst other tested ODTs formulations. Hardness of DM ODTs was not affected by changing the type of superdisintegrant and lubricant. The disintegration time was significantly (p < 0.05) increased by using sodium starch glycolate instead of croscarmellose sodium.
177
Views
4
CrossRef citations
Altmetric
Research Article
Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables
Haitham Fady Mostafa Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University,
Riyadh, Kingdom of Saudi Arabia, Mohamed Abbas Ibrahim Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University,
Riyadh, Kingdom of Saudi ArabiaCorrespondenceabbma71@gmail.com
& Adel Sakr Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University,
Riyadh, Kingdom of Saudi Arabia
Haitham Fady Mostafa Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University,
Riyadh, Kingdom of Saudi Arabia, Mohamed Abbas Ibrahim Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University,
Riyadh, Kingdom of Saudi ArabiaCorrespondenceabbma71@gmail.com
& Adel Sakr Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
& Adel Sakr Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
Pages 454-463
Received 25 Feb 2012
Accepted 22 Jun 2012
Published online: 13 Aug 2012